Molecular action of lenalidomide in lymphocytes and hematologic malignancies
about
Treatment of Cancer Pain by Targeting CytokinesNatural killer cell biology: an update and future directionsSafety and activity of lenalidomide and rituximab in untreated indolent lymphoma: an open-label, phase 2 trial.Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents.Novel insights into the mechanism of action of lenalidomide.Targeting acute myeloid leukemia with a proapoptotic peptide conjugated to a Toll-like receptor 2-mediated cell-penetrating peptide.Immunomodulation of Selective Naive T Cell Functions by p110δ Inactivation Improves the Outcome of Mismatched Cell Transplantation.Development of an Enhanced Phenotypic Screen of Cytotoxic T-Lymphocyte Lytic Granule Exocytosis Suitable for Use with Synthetic Compound and Natural Product Collections.Can lenalidomide play a role in the management of scleritis?Low natural killer (NK) cell counts in peripheral blood adversely affect clinical outcome of patients with follicular lymphoma.Lenalidomide in lymphomas and chronic lymphocytic leukemia.Paraneoplastic inflammation in myelodysplastic syndrome or bone marrow failure: case series with focus on 5-azacytidine and literature review.Emerging immunotherapy and strategies directly targeting B cells for the treatment of diffuse large B-cell lymphoma.New therapies in non-Hodgkin lymphoma.Mechanisms of Action of Lenalidomide in B-Cell Non-Hodgkin LymphomaA calcium- and calpain-dependent pathway determines the response to lenalidomide in myelodysplastic syndromesAutoimmune Syndromes Presenting as a Paraneoplastic Manifestation of Myelodysplastic Syndromes: Clinical Features, Course, Treatment and Outcome.Transfection of chimeric anti-CD138 gene enhances natural killer cell activation and killing of multiple myeloma cells.PD-1 mRNA expression in peripheral blood cells and its modulation characteristics in cancer patients.Prognostic relevance of lymphocytopenia, monocytopenia and lymphocyte-to-monocyte ratio in primary myelodysplastic syndromes: a single center experience in 889 patientsTrial Watch: Lenalidomide-based immunochemotherapy.Very long-lasting remission of refractory T-large granular lymphocytes leukemia and myeloma by lenalidomide treatment.Allogeneic stem cell transplantation and subsequent treatments as a comprehensive strategy for long-term survival of multiple myeloma patients.Increased PD-1/STAT1 ratio may account for the survival benefit in decitabine therapy for lower risk myelodysplastic syndrome.
P2860
Q26779917-8C021460-A8B0-43BE-82B7-ECAD6CE8BB34Q26830512-4E34A6F7-5AC3-4ACF-AC69-55A945CFB6A3Q33418964-12314597-3368-41A2-B6E9-C5DD6EE3FA88Q33657377-E7AD8E88-E29C-4EC3-8621-BE2063A151D8Q34373253-EE7B40D5-689F-4969-AA56-22D038E7643EQ34818576-4C151122-31B2-4C3F-8161-16AF6E544E20Q35973413-110A376E-7EDA-4E18-98C0-7D03E732F984Q35980435-48376D9F-1816-40E8-9104-3132C6D99373Q36986670-329780CA-6584-4089-9719-128A51504E77Q37254746-C268A7E5-D075-4D75-AF94-C6AEEF77C583Q38077277-2AB74EF9-42C2-45A4-81A2-B86B2696ACC2Q38196461-C237168B-5F14-4DD0-B7F0-DA300434C4D8Q38311896-31A4009B-09AA-4B91-B614-6F627B34BEB0Q38315779-FC411686-5C07-4F05-BB7F-070C45A8836AQ38551337-BD43EB5F-7778-402B-8146-96318EF0A449Q38764824-8E9F75D4-7C93-4A89-9FCF-D6245115D6BDQ38921459-B7DFC646-5E25-485B-A121-A9E24FA0AC1CQ39037600-54AB2901-D698-48B5-A475-50111BAEE46CQ41612447-FCEE18B9-BEE9-499D-A2B6-AD0EE3C0CC24Q41870099-BB0BB2FA-7762-4B77-A96A-7D7C2B321BFDQ42737828-C22589C7-7710-41D1-9071-4EBD52878DB3Q45264274-D1ED2DC0-BECF-4C31-85FD-C9C83A38D8A0Q48094910-B88E290B-6216-45F5-83A7-00E5B96E3CBBQ49021366-25F67147-2307-4F8F-ADE7-A547CD4B4E9B
P2860
Molecular action of lenalidomide in lymphocytes and hematologic malignancies
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Molecular action of lenalidomide in lymphocytes and hematologic malignancies
@en
Molecular action of lenalidomide in lymphocytes and hematologic malignancies.
@nl
type
label
Molecular action of lenalidomide in lymphocytes and hematologic malignancies
@en
Molecular action of lenalidomide in lymphocytes and hematologic malignancies.
@nl
prefLabel
Molecular action of lenalidomide in lymphocytes and hematologic malignancies
@en
Molecular action of lenalidomide in lymphocytes and hematologic malignancies.
@nl
P2093
P2860
P356
P1476
Molecular action of lenalidomide in lymphocytes and hematologic malignancies
@en
P2093
Javier Pinilla-Ibarz
Jessica M McDaniel
P K Epling-Burnette
P2860
P304
P356
10.1155/2012/513702
P577
2012-07-24T00:00:00Z